Yunnan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yunnan Zhang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Changjin Zhu
School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 100081, China
1 shared publication Gang Qi
Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
1 shared publication- HuaiJie Zhong
Fujian Normal University
1 shared publication - Huiyun Zhang
Key Lab for Drug Delivery & Tissue Regeneration, Jiangsu Provincial Research Center for Medicinal Function Development of New Food Resources, School of Pharmacy, Jiangsu University, Zhenjiang, 212013, PR China
1 shared publication Junkai Zhu
Faculty of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, China
1 shared publication- Li Qiong Lin
Fuzhou University
1 shared publication
Latest Publications
- Open Access
- 21 May 2026
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 17
Adverse events associated with statin co-use in breast cancer patients: a disproportionality analysis based on the FDA Adverse Event Reporting System
Background: An increasing number of breast cancer patients are using statins concomitantly. However, there are relatively few safety studies on the association between statins and adverse events (AEs) during breast cancer treatment. Objective: This study aims to systematically evaluate the disproportionality signals associated with statin use and the reporting of AEs across different system organ classes (SOCs) in breast cancer patients. Design: This is a pharmacovigilance disproportionality analysis based on the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System database. Methods: All AE reports related to breast cancer from the 2004 Q1 to 2024 Q3 were extracted. Disproportionality analysis was performed using reporting odds ratios (RORs) to detect potential safety signals associated with statin use. Multivariate logistic regression model was used as a secondary analysis to adjust for potential confounders, including age, gender, and therapeutic drugs. Results: A total of 237,868 breast cancer-related AE reports were identified, of which 8,223 involved concomitant statin use. Statin use was associated with lower RORs of hepatobiliary (ROR: 0.60, 95% CI: 0.52–0.68), and blood and lymphatic system disorders (ROR: 0.62, 95% CI: 0.57–0.67). In contrast, higher RORs were observed for skin and subcutaneous tissue (ROR: 1.75, 95% CI: 1.67–1.84), psychiatric (ROR: 1.95, 95% CI: 1.82–2.08), renal and urinary (ROR: 2.03, 95% CI: 1.85–2.22), musculoskeletal and connective tissue (ROR: 1.48, 95% CI: 1.40–1.58), infections and infestations (ROR: 1.25, 95% CI: 1.18–1.34), metabolism and nutrition (ROR: 1.25, 95% CI: 1.16–1.35), gastrointestinal (ROR: 1.10, 95% CI: 1.05–1.16), vascular (ROR: 1.26, 95% CI: 1.16–1.37), nervous system (ROR: 1.20, 95% CI: 1.13–1.27), respiratory, thoracic and mediastinal disorders (ROR: 1.07, 95% CI: 1.00–1.14). Conclusion: In breast cancer patients receiving statins concomitantly, specific disproportionality signals were observed across multiple SOCs. These findings highlight the need for individualized monitoring strategies and further mechanistic studies to clarify the underlying pathways and optimize clinical risk management.
- 21 May 2026
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 17
Open AccessAdverse events associated with statin co-use in breast cancer patients: a disproportionality analysis based on the FDA Adverse Event Reporting System
Background: An increasing number of breast cancer patients are using statins concomitantly. However, there are relatively few safety studies on the association between statins and adverse events (AEs) during breast cancer treatment. Objective: This study aims to systematically evaluate the disproportionality signals associated with statin use and the reporting of AEs across different system organ classes (SOCs) in breast cancer patients. Design: This is a pharmacovigilance disproportionality analysis based on the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System database. Methods: All AE reports related to breast cancer from the 2004 Q1 to 2024 Q3 were extracted. Disproportionality analysis was performed using reporting odds ratios (RORs) to detect potential safety signals associated with statin use. Multivariate logistic regression model was used as a secondary analysis to adjust for potential confounders, including age, gender, and therapeutic drugs. Results: A total of 237,868 breast cancer-related AE reports were identified, of which 8,223 involved concomitant statin use. Statin use was associated with lower RORs of hepatobiliary (ROR: 0.60, 95% CI: 0.52–0.68), and blood and lymphatic system disorders (ROR: 0.62, 95% CI: 0.57–0.67). In contrast, higher RORs were observed for skin and subcutaneous tissue (ROR: 1.75, 95% CI: 1.67–1.84), psychiatric (ROR: 1.95, 95% CI: 1.82–2.08), renal and urinary (ROR: 2.03, 95% CI: 1.85–2.22), musculoskeletal and connective tissue (ROR: 1.48, 95% CI: 1.40–1.58), infections and infestations (ROR: 1.25, 95% CI: 1.18–1.34), metabolism and nutrition (ROR: 1.25, 95% CI: 1.16–1.35), gastrointestinal (ROR: 1.10, 95% CI: 1.05–1.16), vascular (ROR: 1.26, 95% CI: 1.16–1.37), nervous system (ROR: 1.20, 95% CI: 1.13–1.27), respiratory, thoracic and mediastinal disorders (ROR: 1.07, 95% CI: 1.00–1.14). Conclusion: In breast cancer patients receiving statins concomitantly, specific disproportionality signals were observed across multiple SOCs. These findings highlight the need for individualized monitoring strategies and further mechanistic studies to clarify the underlying pathways and optimize clinical risk management.
- 28 November 2022
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (12) , 2383-2386
Concomitant administration of warfarin and toremifene: A case report
Antiestrogen agents have been reported to enhance the anticoagulant activity of warfarin. The use of tamoxifen with warfarin has been contraindicated. However, warfarin in combination with toremifene has not been reported. We report a case in which warfarin was combined with toremifene and applied warfarin dose prediction models to predict the dose of warfarin. We report the case of a 50-year-old woman with a history of breast cancer, who underwent long-term toremifene therapy after mastectomy. The patient was treated with warfarin after prosthetic valve replacement and had a fluctuating international normalized ratio (INR) following the concomitant administration of toremifene. We applied the warfarin dose prediction model to adjust the warfarin dose during treatment. Finally, her INR stabilized with a lower dose of warfarin, and there was no serious bleeding during the 1-year follow-up. Warfarin does not have a serious interaction with toremifene in this case, but it needed about 37.5% dose reduction which was comparable to the interaction of some common antibiotics with warfarin.
- 28 November 2022
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (12) , 2383-2386
Concomitant administration of warfarin and toremifene: A case report
Antiestrogen agents have been reported to enhance the anticoagulant activity of warfarin. The use of tamoxifen with warfarin has been contraindicated. However, warfarin in combination with toremifene has not been reported. We report a case in which warfarin was combined with toremifene and applied warfarin dose prediction models to predict the dose of warfarin. We report the case of a 50-year-old woman with a history of breast cancer, who underwent long-term toremifene therapy after mastectomy. The patient was treated with warfarin after prosthetic valve replacement and had a fluctuating international normalized ratio (INR) following the concomitant administration of toremifene. We applied the warfarin dose prediction model to adjust the warfarin dose during treatment. Finally, her INR stabilized with a lower dose of warfarin, and there was no serious bleeding during the 1-year follow-up. Warfarin does not have a serious interaction with toremifene in this case, but it needed about 37.5% dose reduction which was comparable to the interaction of some common antibiotics with warfarin.
- 18 February 2011
- Published by Springer Nature in Science China Mathematics
- Vol. 54 (4) , 723-740
The approximate Jordan forms of operators on Σ e 1 type Banach spaces
- 18 February 2011
- Published by Springer Nature in Science China Mathematics
- Vol. 54 (4) , 723-740
The approximate Jordan forms of operators on Σ e 1 type Banach spaces